Drug Profile
BI 1265162
Alternative Names: BI-1265162Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antifibrotics
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers) in Netherlands (IV, Liquid)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers) in Netherlands (PO, Liquid)
- 25 Jul 2022 No development reported - Phase-II for Cystic fibrosis (In adolescents, In children, In adults) in United Kingdom, Spain, Belgium, Canada, USA, France, Sweden, Ireland, Germany (Inhalation) (NDR Batch 2022)